Learn about CABLIVI (caplacizumab-yhdp), for adults and children 12 years and older with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) in combination with plasma exchange and immunosuppressive therapy. Please see Important Safety Information and full PI on website.